Sonoma Pharmaceuticals, Inc. (SNOA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SNOA Revenue Growth
Revenue Breakdown (FY 2025)
SNOA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SNOA Revenue Analysis (2014–2025)
As of May 8, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) generated trailing twelve-month (TTM) revenue of $17.7 million, reflecting exceptional growth of +22.0% year-over-year. The most recent quarter (Q3 2026) recorded $4.3 million in revenue, down 22.4% sequentially.
Looking at the longer-term picture, SNOA's 5-year compound annual growth rate (CAGR) stands at -4.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $19.0 million in 2019.
Revenue diversification analysis shows SNOA's business is primarily driven by Human Care (85%), Animal Care (12%), and Service And Royalty (4%). With over half of revenue concentrated in Human Care, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SSKN (-5.2% YoY), DERM (-27.4% YoY), and PRPH (-91.6% YoY), SNOA has outperformed the peer group in terms of revenue growth. Compare SNOA vs SSKN →
SNOA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SNOACurrent | $18M | +22.0% | -4.4% | -26.0% | |
 SSKN | $34M | -5.2% | +1.2% | -27.6% | |
 DERM | $56M | -27.4% | +10.0% | -24.4% | |
 PRPH | $7M | -91.6% | -7.3% | -570.6% | |
 CLSD | $2M | -56.8% | -5.2% | -1735.7% | |
 BRTX | $401,000 | +1.7% | +25.3% | -2881.6% |
SNOA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $14.3M | +12.2% | $5.5M | 38.2% | $-3,710,000 | -26.0% |
| 2024 | $12.7M | -4.0% | $4.7M | 37.3% | $-4,701,000 | -36.9% |
| 2023 | $13.3M | +5.1% | $4.5M | 33.7% | $-4,570,000 | -34.4% |
| 2022 | $12.6M | -32.2% | $4.0M | 31.6% | $-5,887,000 | -46.6% |
| 2021 | $18.6M | +3.9% | $6.6M | 35.2% | $-3,449,000 | -18.5% |
| 2020 | $17.9M | -5.5% | $8.1M | 45.3% | $-7,390,000 | -41.2% |
| 2019 | $19.0M | +13.9% | $8.9M | 46.8% | $-11,258,000 | -59.3% |
| 2018 | $16.7M | +29.9% | $7.3M | 43.9% | $-14,189,000 | -85.2% |
| 2017 | $12.8M | +36.9% | $5.7M | 44.2% | $-12,974,000 | -101.2% |
| 2016 | $9.4M | -32.4% | $2.6M | 28.3% | $-14,714,000 | -157.0% |
See SNOA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNOA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNOA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNOA — Frequently Asked Questions
Quick answers to the most common questions about buying SNOA stock.
Is SNOA's revenue growth accelerating or slowing?
SNOA revenue is accelerating at +22.0% year-over-year, exceeding the 5-year CAGR of -4.4%. TTM revenue reached $18M. Growth momentum has increased versus prior periods.
What is SNOA's long-term revenue growth rate?
Sonoma Pharmaceuticals, Inc.'s 5-year revenue CAGR of -4.4% reflects the sustained expansion pattern. Current YoY growth of +22.0% is above this long-term average.
How is SNOA's revenue distributed by segment?
SNOA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.